CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA
Gespeichert in:
| Veröffentlicht in: | Hematological oncology 2019-06, Vol.37 (S2), p.251-252 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 252 |
|---|---|
| container_issue | S2 |
| container_start_page | 251 |
| container_title | Hematological oncology |
| container_volume | 37 |
| creator | Bobillo, S. Joffe, E. Lavery, J. Noy, A. Palomba, L. Straus, D.J. Kumar, A. Batlevi, C. Horwitz, S. Moskowitz, A. Hamlin, P. Zelenetz, A. Matasar, M. Keudell, G. Sermer, D. Yahalom, J. Dogan, A. Seshan, V. Younes, A. |
| description | |
| doi_str_mv | 10.1002/hon.60_2630 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2242708647</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2242708647</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1080-c04f087fd922298eb17848c9a5cd8671ac067bc586960254ce72feb9e5b4eebd3</originalsourceid><addsrcrecordid>eNp9kM1Kw0AQxxdRsFZPvsCCF0VSJ9t8bI7b7aZZ2DSSpKCnpUk32NIvE4v05iP4jD6JKa1XT8Mwv5n580Po1oaeDUCe3jbrngeaeH04Qx0bgsCywQvOUQeITy0gfXKJrppmAdDOgHbQiis5lpwpzCOWMp6LVGa55Blm4yFOJjlPYpHhJMRZzkYCSzyUYTjJBFYsbfsB5kIprF7j5yiJGb4fqgFXD1iOcR4JnMp88iJjNvj5-hYpu0YX1XTZmJtT7aJJKHIeWSoZHUJYpQ0UrBKcCqhfzQJCSEBNYfvUoWUwdcsZ9Xx7WoLnF6VLvcAD4jql8UllisC4hWNMMet30d3x7rbevO9M86EXm129bl9qQhziA_Ucv6Uej1RZb5qmNpXe1vPVtN5rG_TBp2596pPPlu4f6c_50uz_Q3WUjP-2fgG5V279</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242708647</pqid></control><display><type>article</type><title>CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA</title><source>Access via Wiley Online Library</source><creator>Bobillo, S. ; Joffe, E. ; Lavery, J. ; Noy, A. ; Palomba, L. ; Straus, D.J. ; Kumar, A. ; Batlevi, C. ; Horwitz, S. ; Moskowitz, A. ; Hamlin, P. ; Zelenetz, A. ; Matasar, M. ; Keudell, G. ; Sermer, D. ; Yahalom, J. ; Dogan, A. ; Seshan, V. ; Younes, A.</creator><creatorcontrib>Bobillo, S. ; Joffe, E. ; Lavery, J. ; Noy, A. ; Palomba, L. ; Straus, D.J. ; Kumar, A. ; Batlevi, C. ; Horwitz, S. ; Moskowitz, A. ; Hamlin, P. ; Zelenetz, A. ; Matasar, M. ; Keudell, G. ; Sermer, D. ; Yahalom, J. ; Dogan, A. ; Seshan, V. ; Younes, A.</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.60_2630</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>B-cell lymphoma ; Immunotherapy ; Lymphocytes B ; Lymphoma ; Monoclonal antibodies ; Rituximab ; Targeted cancer therapy</subject><ispartof>Hematological oncology, 2019-06, Vol.37 (S2), p.251-252</ispartof><rights>2019 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhon.60_2630$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhon.60_2630$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27933,27934,45583,45584</link.rule.ids></links><search><creatorcontrib>Bobillo, S.</creatorcontrib><creatorcontrib>Joffe, E.</creatorcontrib><creatorcontrib>Lavery, J.</creatorcontrib><creatorcontrib>Noy, A.</creatorcontrib><creatorcontrib>Palomba, L.</creatorcontrib><creatorcontrib>Straus, D.J.</creatorcontrib><creatorcontrib>Kumar, A.</creatorcontrib><creatorcontrib>Batlevi, C.</creatorcontrib><creatorcontrib>Horwitz, S.</creatorcontrib><creatorcontrib>Moskowitz, A.</creatorcontrib><creatorcontrib>Hamlin, P.</creatorcontrib><creatorcontrib>Zelenetz, A.</creatorcontrib><creatorcontrib>Matasar, M.</creatorcontrib><creatorcontrib>Keudell, G.</creatorcontrib><creatorcontrib>Sermer, D.</creatorcontrib><creatorcontrib>Yahalom, J.</creatorcontrib><creatorcontrib>Dogan, A.</creatorcontrib><creatorcontrib>Seshan, V.</creatorcontrib><creatorcontrib>Younes, A.</creatorcontrib><title>CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA</title><title>Hematological oncology</title><subject>B-cell lymphoma</subject><subject>Immunotherapy</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Monoclonal antibodies</subject><subject>Rituximab</subject><subject>Targeted cancer therapy</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kM1Kw0AQxxdRsFZPvsCCF0VSJ9t8bI7b7aZZ2DSSpKCnpUk32NIvE4v05iP4jD6JKa1XT8Mwv5n580Po1oaeDUCe3jbrngeaeH04Qx0bgsCywQvOUQeITy0gfXKJrppmAdDOgHbQiis5lpwpzCOWMp6LVGa55Blm4yFOJjlPYpHhJMRZzkYCSzyUYTjJBFYsbfsB5kIprF7j5yiJGb4fqgFXD1iOcR4JnMp88iJjNvj5-hYpu0YX1XTZmJtT7aJJKHIeWSoZHUJYpQ0UrBKcCqhfzQJCSEBNYfvUoWUwdcsZ9Xx7WoLnF6VLvcAD4jql8UllisC4hWNMMet30d3x7rbevO9M86EXm129bl9qQhziA_Ucv6Uej1RZb5qmNpXe1vPVtN5rG_TBp2596pPPlu4f6c_50uz_Q3WUjP-2fgG5V279</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Bobillo, S.</creator><creator>Joffe, E.</creator><creator>Lavery, J.</creator><creator>Noy, A.</creator><creator>Palomba, L.</creator><creator>Straus, D.J.</creator><creator>Kumar, A.</creator><creator>Batlevi, C.</creator><creator>Horwitz, S.</creator><creator>Moskowitz, A.</creator><creator>Hamlin, P.</creator><creator>Zelenetz, A.</creator><creator>Matasar, M.</creator><creator>Keudell, G.</creator><creator>Sermer, D.</creator><creator>Yahalom, J.</creator><creator>Dogan, A.</creator><creator>Seshan, V.</creator><creator>Younes, A.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201906</creationdate><title>CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA</title><author>Bobillo, S. ; Joffe, E. ; Lavery, J. ; Noy, A. ; Palomba, L. ; Straus, D.J. ; Kumar, A. ; Batlevi, C. ; Horwitz, S. ; Moskowitz, A. ; Hamlin, P. ; Zelenetz, A. ; Matasar, M. ; Keudell, G. ; Sermer, D. ; Yahalom, J. ; Dogan, A. ; Seshan, V. ; Younes, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1080-c04f087fd922298eb17848c9a5cd8671ac067bc586960254ce72feb9e5b4eebd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>B-cell lymphoma</topic><topic>Immunotherapy</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Monoclonal antibodies</topic><topic>Rituximab</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bobillo, S.</creatorcontrib><creatorcontrib>Joffe, E.</creatorcontrib><creatorcontrib>Lavery, J.</creatorcontrib><creatorcontrib>Noy, A.</creatorcontrib><creatorcontrib>Palomba, L.</creatorcontrib><creatorcontrib>Straus, D.J.</creatorcontrib><creatorcontrib>Kumar, A.</creatorcontrib><creatorcontrib>Batlevi, C.</creatorcontrib><creatorcontrib>Horwitz, S.</creatorcontrib><creatorcontrib>Moskowitz, A.</creatorcontrib><creatorcontrib>Hamlin, P.</creatorcontrib><creatorcontrib>Zelenetz, A.</creatorcontrib><creatorcontrib>Matasar, M.</creatorcontrib><creatorcontrib>Keudell, G.</creatorcontrib><creatorcontrib>Sermer, D.</creatorcontrib><creatorcontrib>Yahalom, J.</creatorcontrib><creatorcontrib>Dogan, A.</creatorcontrib><creatorcontrib>Seshan, V.</creatorcontrib><creatorcontrib>Younes, A.</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bobillo, S.</au><au>Joffe, E.</au><au>Lavery, J.</au><au>Noy, A.</au><au>Palomba, L.</au><au>Straus, D.J.</au><au>Kumar, A.</au><au>Batlevi, C.</au><au>Horwitz, S.</au><au>Moskowitz, A.</au><au>Hamlin, P.</au><au>Zelenetz, A.</au><au>Matasar, M.</au><au>Keudell, G.</au><au>Sermer, D.</au><au>Yahalom, J.</au><au>Dogan, A.</au><au>Seshan, V.</au><au>Younes, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA</atitle><jtitle>Hematological oncology</jtitle><date>2019-06</date><risdate>2019</risdate><volume>37</volume><issue>S2</issue><spage>251</spage><epage>252</epage><pages>251-252</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/hon.60_2630</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0232 |
| ispartof | Hematological oncology, 2019-06, Vol.37 (S2), p.251-252 |
| issn | 0278-0232 1099-1069 |
| language | eng |
| recordid | cdi_proquest_journals_2242708647 |
| source | Access via Wiley Online Library |
| subjects | B-cell lymphoma Immunotherapy Lymphocytes B Lymphoma Monoclonal antibodies Rituximab Targeted cancer therapy |
| title | CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-29T20%3A25%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CLINICAL%20CHARACTERISTICS%20AND%20OUTCOMES%20OF%20STAGE%20I%20DIFFUSE%20LARGE%20B%20CELL%20LYMPHOMA%20(DLBCL)%20IN%20THE%20RITUXIMAB%E2%80%90ERA&rft.jtitle=Hematological%20oncology&rft.au=Bobillo,%20S.&rft.date=2019-06&rft.volume=37&rft.issue=S2&rft.spage=251&rft.epage=252&rft.pages=251-252&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.60_2630&rft_dat=%3Cproquest_cross%3E2242708647%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2242708647&rft_id=info:pmid/&rfr_iscdi=true |